Clinical Trials Directory

Trials / Completed

CompletedNCT06553937

Bioequivalence Study of Macitentan and Tadalafil Film-coated Tablets 10 Mg/40 Mg and 'PrOpsynvi®' Macitentan and Tadalafil Film-coated Tablets 10 Mg/40 Mg

Single Dose Oral Bioequivalence Study of Macitentan and Tadalafil Filmcoated Tablets 10 Mg/40 Mg and 'PrOpsynvi®' Macitentan and Tadalafil Film-coated Tablets 10 Mg/40 Mg in Healthy Adult Male Subjects Under Fed Conditions

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
30 (actual)
Sponsor
Humanis Saglık Anonim Sirketi · Industry
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

Single dose oral bioequivalence study of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg and 'PrOpsynvi®' Macitentan and Tadalafil film-coated tablets 10 mg/40 mg in healthy adult male subjects under fed conditions.

Conditions

Interventions

TypeNameDescription
DRUGMacitentan and Tadalafil1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg
DRUGPrOpsynvi® Film-Coated Tablets1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg

Timeline

Start date
2024-05-10
Primary completion
2024-06-03
Completion
2024-07-31
First posted
2024-08-14
Last updated
2024-09-19

Locations

1 site across 1 country: India

Source: ClinicalTrials.gov record NCT06553937. Inclusion in this directory is not an endorsement.

Bioequivalence Study of Macitentan and Tadalafil Film-coated Tablets 10 Mg/40 Mg and 'PrOpsynvi®' Macitentan and Tadalaf (NCT06553937) · Clinical Trials Directory